FR3008976A1 - "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" - Google Patents

"nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" Download PDF

Info

Publication number
FR3008976A1
FR3008976A1 FR1357265A FR1357265A FR3008976A1 FR 3008976 A1 FR3008976 A1 FR 3008976A1 FR 1357265 A FR1357265 A FR 1357265A FR 1357265 A FR1357265 A FR 1357265A FR 3008976 A1 FR3008976 A1 FR 3008976A1
Authority
FR
France
Prior art keywords
formula
compound
methyl
branched
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR1357265A
Other languages
English (en)
French (fr)
Inventor
Tiran Arnaud Le
Diguarher Thierry Le
Jerome-Benoit Starck
Jean-Michel Henlin
Nanteuil Guillaume De
Olivier Geneste
James Edward Paul Davidson
James Brooke Murray
I-Jen Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Vernalis R&D Ltd
Original Assignee
Les Laboratoires Servier SAS
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50023640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR3008976(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier SAS, Vernalis R&D Ltd filed Critical Les Laboratoires Servier SAS
Priority to FR1357265A priority Critical patent/FR3008976A1/fr
Priority to JOP/2014/0193A priority patent/JO3310B1/ar
Priority to UY35626A priority patent/UY35626A/es
Priority to TW103123060A priority patent/TWI511969B/zh
Priority to ARP140102678A priority patent/AR099913A1/es
Priority to RS20171036A priority patent/RS56451B1/sr
Priority to EP14758605.1A priority patent/EP3024833B1/fr
Priority to PT147586051T priority patent/PT3024833T/pt
Priority to HK16111561.8A priority patent/HK1223360B/xx
Priority to ES14758605.1T priority patent/ES2650814T3/es
Priority to AU2014294867A priority patent/AU2014294867B2/en
Priority to MYPI2016700108A priority patent/MY178251A/en
Priority to SG10201800580XA priority patent/SG10201800580XA/en
Priority to LTEP14758605.1T priority patent/LT3024833T/lt
Priority to MDA20160016A priority patent/MD4643C1/ro
Priority to HK16110596.9A priority patent/HK1222394A1/zh
Priority to PE2016000036A priority patent/PE20160240A1/es
Priority to CN201480052171.7A priority patent/CN105579450B/zh
Priority to NO14758605A priority patent/NO3024833T3/no
Priority to CU2016000011A priority patent/CU24380B1/es
Priority to UAA201601430A priority patent/UA119243C2/uk
Priority to NZ716156A priority patent/NZ716156A/en
Priority to PCT/FR2014/051885 priority patent/WO2015011397A1/fr
Priority to MEP-2017-272A priority patent/ME02922B/me
Priority to HUE14758605A priority patent/HUE037498T4/hu
Priority to DK14758605.1T priority patent/DK3024833T3/en
Priority to MA38803A priority patent/MA38803A1/fr
Priority to SG11201600318RA priority patent/SG11201600318RA/en
Priority to PL14758605T priority patent/PL3024833T3/pl
Priority to HRP20171752TT priority patent/HRP20171752T1/hr
Priority to TN2016000014A priority patent/TN2016000014A1/fr
Priority to US14/906,330 priority patent/US9944620B2/en
Priority to BR112016001328-0A priority patent/BR112016001328B1/pt
Priority to JP2016528588A priority patent/JP6458029B2/ja
Priority to KR1020167004588A priority patent/KR102007516B1/ko
Priority to RU2016105999A priority patent/RU2693629C2/ru
Priority to MX2016000906A priority patent/MX365916B/es
Priority to SI201430461T priority patent/SI3024833T1/sl
Priority to AP2016008990A priority patent/AP2016008990A0/xx
Priority to CA2918217A priority patent/CA2918217C/fr
Priority to GEAP201714062A priority patent/GEP20176804B/en
Priority to EA201600124A priority patent/EA030323B1/ru
Publication of FR3008976A1 publication Critical patent/FR3008976A1/fr
Priority to PH12016500057A priority patent/PH12016500057B1/en
Priority to CL2016000063A priority patent/CL2016000063A1/es
Priority to DO2016000014A priority patent/DOP2016000014A/es
Priority to ZA2016/00350A priority patent/ZA201600350B/en
Priority to CR20160031A priority patent/CR20160031A/es
Priority to NI201600015A priority patent/NI201600015A/es
Priority to IL243742A priority patent/IL243742B/en
Priority to SA516370448A priority patent/SA516370448B1/ar
Priority to GT201600017A priority patent/GT201600017A/es
Priority to CY20171101271T priority patent/CY1119652T1/el
Priority to US15/906,389 priority patent/US10414754B2/en
Priority to US16/532,834 priority patent/US20190359595A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1357265A 2013-07-23 2013-07-23 "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" Pending FR3008976A1 (fr)

Priority Applications (54)

Application Number Priority Date Filing Date Title
FR1357265A FR3008976A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
JOP/2014/0193A JO3310B1 (ar) 2013-07-23 2014-06-16 مشتقات إندوليزين جديدة وطريقة لإنتاجها وتركيبات صيدلانية تحتوي عليها
UY35626A UY35626A (es) 2013-07-23 2014-06-24 Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
TW103123060A TWI511969B (zh) 2013-07-23 2014-07-03 新穎之吲嗪化合物、其製備方法及含彼之醫藥組合物
ARP140102678A AR099913A1 (es) 2013-07-23 2014-07-21 Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
RS20171036A RS56451B1 (sr) 2013-07-23 2014-07-22 Novi derivati indolizina, postupak njihove proizvodnje i farmaceutske kompozicije koje ih sadrže
EP14758605.1A EP3024833B1 (fr) 2013-07-23 2014-07-22 Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
PT147586051T PT3024833T (pt) 2013-07-23 2014-07-22 Novos derivados de indolizina, o seu processo de preparação e as composições farmacêuticas que os contêm
HK16111561.8A HK1223360B (en) 2013-07-23 2014-07-22 Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
ES14758605.1T ES2650814T3 (es) 2013-07-23 2014-07-22 Nuevos derivados de indolizina, procedimiento para su preparación y composiciones farmacéuticas que los contienen
AU2014294867A AU2014294867B2 (en) 2013-07-23 2014-07-22 Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
MYPI2016700108A MY178251A (en) 2013-07-23 2014-07-22 New indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
SG10201800580XA SG10201800580XA (en) 2013-07-23 2014-07-22 Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
LTEP14758605.1T LT3024833T (lt) 2013-07-23 2014-07-22 Nauji indolizino dariniai, jų gamybos būdas ir juos turinčios farmacinės kompozicijos
MDA20160016A MD4643C1 (ro) 2013-07-23 2014-07-22 Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
HK16110596.9A HK1222394A1 (zh) 2013-07-23 2014-07-22 新的吲嗪化合物、其制备方法和包含它们的药物组合物
PE2016000036A PE20160240A1 (es) 2013-07-23 2014-07-22 Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CN201480052171.7A CN105579450B (zh) 2013-07-23 2014-07-22 新的吲嗪化合物、其制备方法和包含它们的药物组合物
NO14758605A NO3024833T3 (cg-RX-API-DMAC7.html) 2013-07-23 2014-07-22
CU2016000011A CU24380B1 (es) 2013-07-23 2014-07-22 Derivados de 3- [2- (3,4-dihidroisoquinolin-2 (1 h) -ilcarbonil) fenil] -n- (4-hidroxifenil) -n-fenil-5,6,7,8 - tetrahidroindolizina -1-carboxamida útiles como inhibidores bcl-2 antiapoptóticos, y composiciones farmacéuticas que los contienen
UAA201601430A UA119243C2 (uk) 2013-07-23 2014-07-22 Сполуки індолізину, спосіб їх одержання і фармацевтичні композиції, що їх містять
NZ716156A NZ716156A (en) 2013-07-23 2014-07-22 Novel indolizine derivatives useful as bcl-2 inhibitors, method for the production thereof and pharmaceutical compositions containing same
PCT/FR2014/051885 WO2015011397A1 (fr) 2013-07-23 2014-07-22 Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
MEP-2017-272A ME02922B (me) 2013-07-23 2014-07-22 Novi derivati indolizina, postupak njihove proizvodnje i farmaceutske kompozicije koje ih sadrže
HUE14758605A HUE037498T4 (hu) 2013-07-23 2014-07-22 Új indolizin származékok, elõállítási eljárásuk és ezeket tartalmazó gyógyszerészeti készítmények
DK14758605.1T DK3024833T3 (en) 2013-07-23 2014-07-22 NEW INDOLIZIN DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MA38803A MA38803A1 (fr) 2013-07-23 2014-07-22 Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
SG11201600318RA SG11201600318RA (en) 2013-07-23 2014-07-22 Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
PL14758605T PL3024833T3 (pl) 2013-07-23 2014-07-22 Nowe pochodne indolizyny, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające
HRP20171752TT HRP20171752T1 (hr) 2013-07-23 2014-07-22 Novi derivati indolizina, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže
TN2016000014A TN2016000014A1 (fr) 2013-07-23 2014-07-22 Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US14/906,330 US9944620B2 (en) 2013-07-23 2014-07-22 Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
BR112016001328-0A BR112016001328B1 (pt) 2013-07-23 2014-07-22 Compostos derivados de indolizina, composição farmacêutica e combinação que os compreendem, seus usos e processo para a preparação dos mesmos
JP2016528588A JP6458029B2 (ja) 2013-07-23 2014-07-22 新規なインドリジン誘導体、それらの製造方法及びそれらを含有する医薬組成物
KR1020167004588A KR102007516B1 (ko) 2013-07-23 2014-07-22 신규한 인돌리진 유도체, 이의 생성을 위한 방법 및 이를 함유하는 약학적 조성물
RU2016105999A RU2693629C2 (ru) 2013-07-23 2014-07-22 Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
MX2016000906A MX365916B (es) 2013-07-23 2014-07-22 Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
SI201430461T SI3024833T1 (sl) 2013-07-23 2014-07-22 Novi derivati indolizina, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
AP2016008990A AP2016008990A0 (en) 2013-07-23 2014-07-22 New indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
CA2918217A CA2918217C (fr) 2013-07-23 2014-07-22 Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GEAP201714062A GEP20176804B (en) 2013-07-23 2014-07-22 Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
EA201600124A EA030323B1 (ru) 2013-07-23 2014-07-22 Индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
PH12016500057A PH12016500057B1 (en) 2013-07-23 2016-01-08 Novel indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
CL2016000063A CL2016000063A1 (es) 2013-07-23 2016-01-12 Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
DO2016000014A DOP2016000014A (es) 2013-07-23 2016-01-13 Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ZA2016/00350A ZA201600350B (en) 2013-07-23 2016-01-15 Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
CR20160031A CR20160031A (es) 2013-07-23 2016-01-15 Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
NI201600015A NI201600015A (es) 2013-07-23 2016-01-21 Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
IL243742A IL243742B (en) 2013-07-23 2016-01-21 New indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
SA516370448A SA516370448B1 (ar) 2013-07-23 2016-01-21 مركبات إندوليزين جديدة ، وعملية لتحضيرها وتركيبات صيدلية تحتوى عليها‏
GT201600017A GT201600017A (es) 2013-07-23 2016-01-22 Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CY20171101271T CY1119652T1 (el) 2013-07-23 2017-12-05 Νεα παραγωγα ινδολιζινης, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν
US15/906,389 US10414754B2 (en) 2013-07-23 2018-02-27 Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
US16/532,834 US20190359595A1 (en) 2013-07-23 2019-08-06 Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357265A FR3008976A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"

Publications (1)

Publication Number Publication Date
FR3008976A1 true FR3008976A1 (fr) 2015-01-30

Family

ID=50023640

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1357265A Pending FR3008976A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"

Country Status (50)

Country Link
US (3) US9944620B2 (cg-RX-API-DMAC7.html)
EP (1) EP3024833B1 (cg-RX-API-DMAC7.html)
JP (1) JP6458029B2 (cg-RX-API-DMAC7.html)
KR (1) KR102007516B1 (cg-RX-API-DMAC7.html)
CN (1) CN105579450B (cg-RX-API-DMAC7.html)
AP (1) AP2016008990A0 (cg-RX-API-DMAC7.html)
AR (1) AR099913A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014294867B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016001328B1 (cg-RX-API-DMAC7.html)
CA (1) CA2918217C (cg-RX-API-DMAC7.html)
CL (1) CL2016000063A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160031A (cg-RX-API-DMAC7.html)
CU (1) CU24380B1 (cg-RX-API-DMAC7.html)
CY (1) CY1119652T1 (cg-RX-API-DMAC7.html)
DK (1) DK3024833T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2016000014A (cg-RX-API-DMAC7.html)
EA (1) EA030323B1 (cg-RX-API-DMAC7.html)
ES (1) ES2650814T3 (cg-RX-API-DMAC7.html)
FR (1) FR3008976A1 (cg-RX-API-DMAC7.html)
GE (1) GEP20176804B (cg-RX-API-DMAC7.html)
GT (1) GT201600017A (cg-RX-API-DMAC7.html)
HK (1) HK1222394A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20171752T1 (cg-RX-API-DMAC7.html)
HU (1) HUE037498T4 (cg-RX-API-DMAC7.html)
IL (1) IL243742B (cg-RX-API-DMAC7.html)
JO (1) JO3310B1 (cg-RX-API-DMAC7.html)
LT (1) LT3024833T (cg-RX-API-DMAC7.html)
MA (1) MA38803A1 (cg-RX-API-DMAC7.html)
MD (1) MD4643C1 (cg-RX-API-DMAC7.html)
ME (1) ME02922B (cg-RX-API-DMAC7.html)
MX (1) MX365916B (cg-RX-API-DMAC7.html)
MY (1) MY178251A (cg-RX-API-DMAC7.html)
NI (1) NI201600015A (cg-RX-API-DMAC7.html)
NO (1) NO3024833T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ716156A (cg-RX-API-DMAC7.html)
PE (1) PE20160240A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016500057B1 (cg-RX-API-DMAC7.html)
PL (1) PL3024833T3 (cg-RX-API-DMAC7.html)
PT (1) PT3024833T (cg-RX-API-DMAC7.html)
RS (1) RS56451B1 (cg-RX-API-DMAC7.html)
RU (1) RU2693629C2 (cg-RX-API-DMAC7.html)
SA (1) SA516370448B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201800580XA (cg-RX-API-DMAC7.html)
SI (1) SI3024833T1 (cg-RX-API-DMAC7.html)
TN (1) TN2016000014A1 (cg-RX-API-DMAC7.html)
TW (1) TWI511969B (cg-RX-API-DMAC7.html)
UA (1) UA119243C2 (cg-RX-API-DMAC7.html)
UY (1) UY35626A (cg-RX-API-DMAC7.html)
WO (1) WO2015011397A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201600350B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511750A (zh) * 2017-10-25 2020-08-07 法国施维雅药厂 新的大环衍生物、其制备方法以及包含其的药物组合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
US11814734B2 (en) * 2019-05-13 2023-11-14 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
CN116981458A (zh) * 2021-03-12 2023-10-31 伊尔治疗学股份有限公司 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物
WO2023129553A1 (en) * 2021-12-29 2023-07-06 Eil Therapeutics, Inc. Bcl-2 inhibitors
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023778A2 (en) * 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
WO2012162365A1 (en) * 2011-05-25 2012-11-29 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
WO2013110890A1 (fr) * 2012-01-24 2013-08-01 Les Laboratoires Servier Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100391958C (zh) * 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
CN101039662A (zh) * 2004-08-20 2007-09-19 密执安州立大学董事会 抗-细胞凋亡bcl-2家族成员的小分子抑制剂及其应用
WO2007075783A2 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
US7902218B2 (en) 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
KR101511074B1 (ko) 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Mcl-1 억제제
US8263607B2 (en) 2007-05-22 2012-09-11 Astellas Pharma Inc. 1-substituted tetrahydroisoquinoline compound
CN102007101A (zh) 2007-11-30 2011-04-06 生物区科学管理控股有限公司 作为抗菌剂的四氢-异喹啉ppat抑制剂
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ,インコーポレーテッド 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法
WO2009102488A2 (en) 2008-02-15 2009-08-20 Tufts University A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
AU2012355623A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EA201491265A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
AU2012355624A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
DK2609926T3 (da) 2011-12-30 2014-01-06 Jakob Hraschan Forebyggelse eller behandling af smertefulde polyneuropatier ved administration af et aluminiumsilikat
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023778A2 (en) * 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
WO2012162365A1 (en) * 2011-05-25 2012-11-29 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
WO2013110890A1 (fr) * 2012-01-24 2013-08-01 Les Laboratoires Servier Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511750A (zh) * 2017-10-25 2020-08-07 法国施维雅药厂 新的大环衍生物、其制备方法以及包含其的药物组合物
CN111511750B (zh) * 2017-10-25 2023-06-13 法国施维雅药厂 大环衍生物、其制备方法以及包含其的药物组合物

Also Published As

Publication number Publication date
CL2016000063A1 (es) 2016-08-19
UY35626A (es) 2015-02-27
SG11201600318RA (en) 2016-02-26
TWI511969B (zh) 2015-12-11
RU2693629C2 (ru) 2019-07-03
UA119243C2 (uk) 2019-05-27
KR20160034387A (ko) 2016-03-29
RU2016105999A (ru) 2017-08-28
NO3024833T3 (cg-RX-API-DMAC7.html) 2018-02-03
JP2016525536A (ja) 2016-08-25
PH12016500057A1 (en) 2016-03-28
AU2014294867A1 (en) 2016-02-11
MY178251A (en) 2020-10-07
RS56451B1 (sr) 2018-01-31
US9944620B2 (en) 2018-04-17
US20180186771A1 (en) 2018-07-05
BR112016001328A2 (cg-RX-API-DMAC7.html) 2017-07-25
NZ716156A (en) 2019-05-31
HUE037498T2 (hu) 2018-08-28
WO2015011397A1 (fr) 2015-01-29
CN105579450B (zh) 2017-12-12
HK1222394A1 (zh) 2017-06-30
TN2016000014A1 (fr) 2017-07-05
JO3310B1 (ar) 2018-09-16
HRP20171752T1 (hr) 2017-12-29
PE20160240A1 (es) 2016-04-30
GT201600017A (es) 2018-10-08
CA2918217A1 (fr) 2015-01-29
RU2016105999A3 (cg-RX-API-DMAC7.html) 2018-04-28
US20160176848A1 (en) 2016-06-23
MD20160016A2 (ro) 2016-07-31
EP3024833B1 (fr) 2017-09-06
NI201600015A (es) 2016-02-11
MX2016000906A (es) 2016-05-05
TW201504238A (zh) 2015-02-01
MD4643B1 (ro) 2019-08-31
AU2014294867B2 (en) 2018-10-04
ZA201600350B (en) 2017-05-31
JP6458029B2 (ja) 2019-01-23
AR099913A1 (es) 2016-08-31
EP3024833A1 (fr) 2016-06-01
ME02922B (me) 2018-04-20
EA030323B1 (ru) 2018-07-31
BR112016001328B1 (pt) 2022-03-03
PL3024833T3 (pl) 2018-02-28
MA38803A1 (fr) 2017-10-31
US10414754B2 (en) 2019-09-17
MD4643C1 (ro) 2020-03-31
SI3024833T1 (sl) 2017-12-29
PT3024833T (pt) 2017-10-06
SG10201800580XA (en) 2018-03-28
LT3024833T (lt) 2017-10-25
GEP20176804B (en) 2018-01-10
CR20160031A (es) 2016-04-04
ES2650814T3 (es) 2018-01-22
KR102007516B1 (ko) 2019-08-05
CN105579450A (zh) 2016-05-11
MX365916B (es) 2019-06-20
CY1119652T1 (el) 2018-04-04
US20190359595A1 (en) 2019-11-28
IL243742B (en) 2019-06-30
HUE037498T4 (hu) 2018-11-28
CU24380B1 (es) 2019-02-04
AP2016008990A0 (en) 2016-01-31
EA201600124A1 (ru) 2016-07-29
DOP2016000014A (es) 2016-03-15
PH12016500057B1 (en) 2016-03-28
DK3024833T3 (en) 2017-12-18
HK1223360A1 (zh) 2017-07-28
CA2918217C (fr) 2018-06-12
CU20160011A7 (es) 2016-05-30
SA516370448B1 (ar) 2018-12-12
IL243742A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
CA2918217C (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2807159B1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent pour le traitement du cancer
CA2856886C (fr) Nouveaux derives phosphates, leur utilisation en cancerologie, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2856505C (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2917965C (fr) Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2730516A1 (fr) Nouveaux derives tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
OA17865A (fr) Nouveaux dérivés d'Indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
OA16963A (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
OA16962A (fr) Nouveaux dérivés phosphates, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5